Diabetic Nephropathy News | Diabetes & Renal Research Studies

Diabetic Nephropathy


Canagliflozin Protects Against Renal Function Decline in Advanced Diabetic CKD

WASHINGTON—Canagliflozin showed a protective effect against kidney function decline in patients with type 2 diabetes and a baseline estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2, new study findings presented at the American Society of Nephrology’s Kidney Week 2019 meeting suggest. The findings are from a post-hoc subgroup analysis of the phase 3 CREDENCE…
kidney cross section

FDA Approves Canagliflozin for Diabetic Kidney Disease

FDA’s approval of canagliflozin for slowing progression of diabetic nephropathy in patients with type 2 diabetes makes the drug the first new treatment option in nearly 20 years indicated for slowing diabetic kidney disease in these patients.
Next post in Diabetic Nephropathy